Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - Safety and efficacy in 1,032 patients with hematologic malignancy

Thrombosis Research

Volumn 133, Issue 3, 2014, Pages 364-370

  Asakura, Hidesaku ^a   Takahashi, Hoyu ^b   Tsuji, Hajime ^c   Matsushita, Tadashi ^d   Ninomiya, Hideyuki ^e   Honda, Goichi ^e   Mimuro, Jun ^f   Eguchi, Yutaka ^g   Kitajima, Isao ^h   Sakata, Yoichi ^f  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b Niigata Prefectural Kamo Hospital   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

^e ASAHI KASEI PHARMA CORPORATION   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^h UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Disseminated intravascular coagulation; Hematologic malignancy; Post marketing surveillance; Thrombomodulin

Indexed keywords

RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ADOLESCENT; ADULT; AGED; BLOOD; CHILD; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMAN; INFANT; MALE; MIDDLE AGED; NEWBORN; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOMODULIN; YOUNG ADULT;

EID: 84893970510     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.12.033     Document Type: Article

References (40)

1. M. Levi, and H. Ten Cate Disseminated intravascular coagulation N Engl J Med 341 8 1999 586 592
2. R.L. Bick Disseminated intravascular coagulation: current concepts of etiology, pathophysiology, diagnosis, and treatment Hematol Oncol Clin North Am 17 1 2003 149 176
3. C.H. Toh, and M. Dennis Disseminated intravascular coagulation: old disease, new hope BML 327 7421 2003 974 977
4. H. Wada, T. Nagano, M. Tomeoku, M. Kuto, Y. Karitani, and K. Deguchi et al. Coagulant and fibrinolytic activities in the leukemic cell lysates Thromb Res 30 4 1983 315 322
5. H. Wada, Y. Kumeda, Z. Ogasawara, M. Ohiwa, T. Kaneko, and S. Tamaki et al. Plasminogen activators and their inhibitors in leukemic cell homogenates Am J Hematol 42 2 1993 166 170
6. C. Arbuthnot, and J.T. Wilde Haemostatic problems in acute promyelocytic leukemia Blood Rev 20 6 2006 289 297
7. M.S. Tallman, S.A. Abutalib, and J.K. Altman The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia Semin Thromb Hemost 33 4 2007 330 338
8. M. Franchini, M.N. Dario Di Minno, and A. Coppola Disseminated intravascular coagulation in hematologic malignancies Semin Thromb Hemost 36 4 2010 388 403
9. M. Levi, C.H. Toh, J. Thachil, and H.G. Watson Guidelines for the diagnosis and management of disseminated intravascular coagulation Br J Haematol 145 1 2009 24 33
10. H. Wada, H. Asakura, K. Okamoto, T. Iba, T. Uchiyama, and K. Kawasugi et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan Thromb Res 125 1 2010 6 11
11. I. Maruyama Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation Thromb Haemost 82 2 1999 718 721
12. C.T. Esmon The interactions between inflammation and coagulation Br J Haematol 131 4 2005 417 430
13. B.N. Bouma, and J.C. Meijers Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) J Thromb Haemost 1 7 2003 1566 1574
14. Y. Shimomura, T. Kawamura, H. Komura, W. Campbell, N. Okada, and H. Okada Modulation of procarboxypeptidase R(Pro R) activation by complementary peptides to thrombomodulin Microbiol Immunol 47 3 2003 241 245
15. E.M. Conway, M. Van de Wouwer, S. Pollefeyt, K. Jurk, H. Van Aken, and A. De Vriese et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kB and mitogen-activated protein kinase pathways J Exp Med 196 5 2002 565 577
16. K. Abeyama, D.M. Stern, Y. Ito, K. Kawahara, Y. Yoshimoto, and M. Tanaka et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism J Clin Invest 115 5 2005 1267 1274
17. C.S. Shi, G.Y. Shi, S.M. Hsiao, Y.C. Kao, K.L. Kuo, and C.Y. Ma et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response Blood 112 9 2008 3661 3670
18. H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, and R. Ohno et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial J Thromb Haemost 5 1 2007 31 41
19. J. Mimuro, H. Takahashi, I. Kitajima, H. Tsuji, Y. Eguchi, and T. Matsushita et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation Thromb Res 131 5 2013 436 443
20. S. Niimi, T. Oshizawa, M. Naotsuka, S. Ohba, A. Yokozawa, and T. Murata et al. Establishment of a standard assay method for human thrombomodulin and determination of the activity of the Japanese reference standard Biologicals 30 2002 69 76
21. K. Tsuruta, Y. Yamada, M. Serada, and Y. Tanigawara Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects J Clin Pharmacol 51 2011 1276 1285
22. Northrop Grumman Corporation MedDRA and MSSO. Northrop Grumman Corporation website http://www.Meddramsso.com April 8, 2011
23. ICH Steering Committee ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting. Pharmaceuticals and Medical Devices Agency website http://www.pmda.go.jp/ich/e/ e2a-95-3-20e.pdf April 8, 2011
24. N. Kobayashi, T. Maekawa, M. Takada, H. Tanaka, and H. Gonmori Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan Bibl Haematol 49 1983 265 275
25. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1 1976 31 41
26. C.H. Pui, R.K. Dodge, G.V. Dahl, G. Rivera, A.T. Look, and D. Kalwinsky et al. Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia Blood 66 4 1985 778 782
27. F. Ferrara, and S. Mirto Serum LDH value as a predictor of clinical outcome in acute myelogenous leukemia of the elderly Br J Haematol 92 3 1996 627 631
28. K. Kawasugi, H. Wada, T. Hatada, K. Okamoto, T. Uchiyama, and S. Kushimoto et al. Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases Thromb Res 128 2 2011 186 190
29. N. Aikawa, S. Shimazaki, Y. Yamamoto, H. Saito, I. Maruyama, and R. Ohno et al. Thrombomodulin α in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial Shock 35 4 2011 349 354
30. N.S. Majhail, and A.E. Lichtin Acute leukemia with a very high leukocyte count: confronting a medical emergency Cleve Clin J Med 71 8 2004 633 637
31. M.C. Chang, T.Y. Chen, J.L. Tang, Y.J. Lan, T.Y. Chao, and C.F. Chiu et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage Am J Hematol 82 11 2007 976 980
32. M.M. McDonald, M.L. Johnson, C.M. Rumack, B.L. Koops, M.A. Guggenheim, and C. Babb et al. Role of coagulopathy in newborn intracranial hemorrhage Pediatrics 74 1 1984 26 31
33. M. Andrew The hemostatic system in the infant D.G. Nathan, F.A. Osky, Hematology of infancy and childhood 1993 WB Saunders Co. Philadelphia 591 668
34. S. Kusuda, M. Fujimura, I. Sakuma, H. Aotani, K. Kabe, and Y. Itani et al. Neonatal Research Network, Japan. Morbidity and mortality of infants with very low birth weight in Japan: center variation Pediatrics 118 4 2006 e1130 e1138 [Epub 2006 Sep 1]
35. A. El Beshlawy, I. Alaraby, H. Abou Hussein, and H.H. Abou-Elew Mohamed Abdel Kader MS. Study of protein C, protein S, and antithrombin III in newborns with sepsis Pediatr Crit Care Med 11 1 2010 52 59
36. F.B. Taylor Jr., C.H. Toh, W.K. Hoots, H. Wada, and M. Levi Scientific subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Thromb Haemost 86 5 2001 1327 1330
37. S. Gando, T. Iba, Y. Eguchi, Y. Ohtomo, K. Okamoto, and K. Koseki et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria Crit Care Med 34 3 2006 625 631
38. H. Wada, J. Thachil, M. Nisio, P. Mathew, S. Kurosawa, and S. Gando et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines J Thromb Haemost 11 11 2013 2078 2079
39. J. Yang, T. Ikezoe, C. Nishioka, G. Honda, and A. Yokoyama Thrombomodulin-induced differentiation of acute myelomonocytic leukemia cells via JNK signaling Leuk Res 36 5 2012 625 633
40. T. Ikezoe, J. Yang, C. Nishioka, M. Isaka, N. Iwabu, and M. Sakai et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells Exp Hematol 40 6 2012 457 465